B
Bull
Bull · 25%NVO
$87.35
Scenario price
$39.050
-0.375 (-0.96%)At close
Loading chart…
- High
- 39.290
- Open
- 39.210
- VWAP
- 39.03
- Volume
- 9.19M
- Mkt Cap
- 643.52B
- Low
- 38.750
- Amount
- 358.62M
- EV/EBITDA, TTM
- 1.71
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
AI analysis of Novo Nordisk A/S (NVO)
HoldNovo Nordisk A/S (NVO) is currently priced at $39.05, which is below the average analyst price target of $43.67. However, the stock has a year-to-date change of -25.46%, indicating significant downward pressure. While the company has strong gross margins of 84.80% and a forward P/E ratio of 11.83, the risk of patent expiration for key products in 2032 could impact future revenues. Given these factors, it may be prudent to hold rather than buy at this time.
Analyst Ratings (1)
+40.00% upside
Hold
0 Buy
1 Hold
0 Sell
Current: 39.05
Low
42.00
Average
54.67
High
70.00
BMO Capital
Market Perform
$40
2026-10-12
BMO Capital
2026-10-12
Price Target
$40
Market Perform
Citi
Neutral
—
2026-10-09
Citi
2026-10-09
Price Target
—
Neutral
Deutsche Bank
Sell
—
2026-09-22
Deutsche Bank
2026-09-22
Price Target
—
Sell
Morgan Stanley
Underweight
$40
2026-09-11
Morgan Stanley
2026-09-11
Price Target
$40
Underweight
HSBC
Hold
—
2026-09-10
HSBC
2026-09-10
Price Target
—
Hold
Valuation Metrics
The current forward P/E ratio for Novo Nordisk A/S (NVO) is 11.83, compared to its 5-year average forward P/E of 25.61.
Alphio AI Price Scenarios for NVO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NVO
Events Timeline
News
9.510-25CNBCCritical Earnings Week Ahead Amid Fed Meeting and Inflation Data
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
9.510-22FoolBristol-Myers Squibb Maintains Stable Revenue Growth
7.010-21FoolNovo Nordisk's Outlook for the Next Decade
9.010-21FoolNovo Nordisk Reports Promising Phase 3 Results for CagriSema
NVO FAQ — answered by Alphio AI
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Novo Nordisk A/S (NVO) is currently priced at $39.05, which is below the average analyst price target of $43.67. However, the stock has a year-to-date change of -25.46%, indicating significant downward pressure. While the company has strong gross margins of 84.80% and a forward P/E ratio of 11.83, the risk of patent expiration for key products in 2032 could impact future revenues. Given these factors, it may be prudent to hold rather than buy at this time.
1 analysts cover NVO: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 54.67.
Community
More ↗
👀 Looking for the bigger upside in obesity stocks? $NVO vs. $VKTX Novo Nordisk has blockbuster drugs and an established commercial business. Viking Therapeutics is betting on a different opportunity: turning VK2735 into a contender in both oral and injectable obesity treatments. 🔥 Why $VKTX could stand out: 💊 Oral and injectable VK2735 now in Phase 3 📊 Maintenance data showed 90% of prior weight loss retained with every-other-week dosing and 85% with monthly dosing 🚀 A potential differentiator in long-term weight management ⚠️ The trade-off? VKTX has no marketed products yet, making it a higher-risk bet than NVO. 🎯 Which obesity stock offers the better opportunity? Compare the bull case for $VKTX vs. $NVO here 👇
Show more
$NVO 25 years, quarterly candles chart updated. It would be fantastic to end the year with that huge bullish signal activated. This is a buy & hold stock for long term investors. 4.5% dividend.
Show more
🚨 $VKTX just took a major step toward bringing its obesity pill to market! Viking Therapeutics has initiated two Phase 3 trials of oral VK2735, targeting patients with obesity both with and without Type 2 diabetes. 📊 Phase 2 results showed up to 12.2% mean weight loss in just 13 weeks, versus 1.3% with placebo. 🔥 The bigger picture? > Injectable VK2735 is already in Phase 3, with enrollment completed in both studies. > Maintenance data showed patients retained 85–90% of prior weight loss with less frequent injections. > Oral maintenance research and VK3019 add further potential to the pipeline. Competition from $LLY and $NVO is heating up, but Viking is expanding its options across oral, injectable and maintenance treatments.
Show more
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.